What is Zacks Research’s Estimate for Soligenix Q2 Earnings?

Soligenix Inc. (NASDAQ:SNGX) – Stock analysts at Zacks Research boosted their Q2 2026 earnings per share estimates for shares of Soligenix in a report issued on Thursday, May 14th. Zacks Research analyst D. Bautz now anticipates that the biopharmaceutical company will post earnings of ($0.22) per share for the quarter, up from their previous estimate of ($0.30). The consensus estimate for Soligenix’s current full-year earnings is ($1.14) per share. Zacks Research also issued estimates for Soligenix’s Q3 2026 earnings at ($0.21) EPS, Q4 2026 earnings at ($0.21) EPS, FY2026 earnings at ($0.90) EPS, FY2027 earnings at ($0.67) EPS and FY2028 earnings at ($0.72) EPS.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Soligenix in a report on Tuesday, April 21st. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Soligenix presently has an average rating of “Hold” and a consensus price target of $6.00.

Soligenix Stock Performance

Shares of NASDAQ:SNGX opened at $0.41 on Tuesday. The business’s fifty day moving average price is $0.99 and its two-hundred day moving average price is $1.22. The stock has a market cap of $6.06 million, a PE ratio of -0.24 and a beta of 1.31. Soligenix has a one year low of $0.28 and a one year high of $6.23.

Soligenix (NASDAQ:SNGX) last released its quarterly earnings results on Friday, May 8th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.02.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in SNGX. Banco BTG Pactual S.A. purchased a new position in Soligenix in the third quarter valued at about $54,000. Sabby Management LLC purchased a new position in Soligenix in the third quarter valued at about $94,000. Two Sigma Investments LP purchased a new position in Soligenix in the third quarter valued at about $102,000. Virtu Financial LLC purchased a new position in Soligenix in the third quarter valued at about $59,000. Finally, Armistice Capital LLC purchased a new position in Soligenix in the third quarter valued at about $821,000. 3.60% of the stock is owned by hedge funds and other institutional investors.

About Soligenix

Soligenix, Inc is a clinical‐stage biopharmaceutical company focused on developing vaccines and therapeutics to address unmet medical needs in rare diseases and biodefense. The company leverages proprietary technologies to create novel vaccine adjuvants, small‐molecule innate defense regulators and photodynamic therapies aimed at improving patient outcomes in orphan indications and protecting public health against biological threats.

The company’s pipeline is organized into two core divisions.